Pre-Test Tackling Myths about Long-Acting Injectables in Schizophrenia: LAIs are Too Difficult to Implement in Practice (Module 4) Pre-Test Rebecca is a 31-year-old woman living with schizophrenia who has had prior trials of aripiprazole, olanzapine, risperidone, and quetiapine. She was prescribed each of these medications for 9-12 months until they were discontinued due to lack of efficacy when a psychotic relapse occurred. She lives with her parents and helps her father, who has Type 1 diabetes, take his insulin injections. She says she feels comfortable with small needles but larger needles make her uncomfortable since a traumatic situation involving emergent forced IM medications when she became violent during a prior hospitalization. Which of the following LAIs would be the best overall choice for her? Aripiprazole lauroxil Aripiprazole monohydrate Haloperidol decanoate Paliperidone palmitate Risperidone subcutaneous LAI Unsure Please now rate your ability to use currently available therapies to manage schizophrenia. Excellent Very Good Good Excellent Fair Poor
